Ac Immune Sa recorded a cumulative net loss of $-96 million during 12 month ending in the fourth quarter 2025.
The Healthcare sector has seen employees of 307 other companies achieving higher income per employee. While Ac Immune Sa's total ranking has deteriorated compared to the previous quarter from 0 to 4335.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ACIU Net Income per Employee	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-1,747,467	-1,392,358	-1,392,358	-1,383,200	-1,383,200
ACIU's Total Ranking	# 4335	# 0	#	#	#
Seq. Net Income Change	-	-	-	-	-

ACIU Company Profile >> Back to ACIU Efficiency Comparisons >> Compare ACIU Net Income per Employee to its Competitors

ACIU Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 308
Healthcare Sector	# 738
Overall Market	# 4335

Net Income per Employee Statistics
High	Average	Low
$ -925,745	$ -1,161,255	$ -1,327,200
(Dec 31 2024)		(Dec 31 2021)

News about Ac Immune Sa Income per employee

AC Immune Celebrates Key Advancements in Alzheimerns Research: Milestone Payment and Fast Track Designation for Groundbreaking Diagnostic and Treatment Solutions

Swiss-based biopharmaceutical company AC Immune is making significant strides in the fight against neurodegenerative diseases, particularly Alzheimerns disease (AD). The company recently announced the receipt of a second milestone payment following promising developments in its Phase 2b ReTain trial of the investigational drug ACI-35.030. This milestone symbolizes a pivotal advancement in the quest for effective therapies aimed at addressing early-stage Alzheimerns disease, underscoring AC Immunens commitment to innovation and precision in neurodegenerative research.
In a parallel vein of development, AC Immune has also garnered attention for its innovative imaging agent, PI-2620 Tau-PET, which has received Fast Track designation from the U.S. Food and Drug Administration (FDA). This recognition is granted for three serious neurodegenerative conditions: Alzheimer’s Disease, Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD). The Fast Track designation signifies an accelerated pathway for the potential clinical utilization of PI-2620, facilitating quicker access to crucial diagnostic tools for both clinicians and patients as they navigate the complexities of these diseases.

Companies with similar Income per Employee for 12 month ending Dec 31 2025, within Healthcare Sector

Income per Employee

Income 12 month ending Dec 31 2025

Number of Employees Dec 31 2025

Date modified: 2026-07-07T08:55:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.